This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hussein, M. A. Search for Related Content PubMed PubMed Citation Articles by Hussein, M. A.

Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide

Cleveland Clinic Myeloma Research Program, Cleveland, Ohio, USA

Correspondence: Mohamad A. Hussein, M.D., Cleveland Clinic Myeloma Research Program, 9500 Euclid Avenue, R-35, Cleveland, Ohio 44195, USA. Telephone: 216-445-6830; Fax: 216-445-3434; e-mail: husseim{at}ccf.org or mah{at}runbox.com

The combination of vincristine, doxorubicin, and dexamethasone is an effective treatment for multiple myeloma that produces a more rapid response than other regimens, probably a function of the high-dose, intense steroid schedule. However, vincristine/doxorubicin/dexamethasone administration requires a 96-hour continuous infusion delivered via a central venous catheter, which necessitates hospitalization in a large number of patients and may increase the risk for infection. Moreover, the high dosages of corticosteroids required with this regimen can cause substantial toxicity. Therefore, a number of modifications to the regimen have been evaluated in an effort to improve its tolerability and efficacy. These include replacing doxorubicin with pegylated liposomal doxorubicin and using a reduced frequency of dexamethasone, and, later, the addition of thalidomide. The results of an ongoing study demonstrated that this latest regimen (including thalidomide) is associated with an improved response rate and a higher quality of response compared with previous regimens in patients with relapsed/refractory multiple myeloma. This modified regimen is well tolerated when prophylactic and supportive measures are incorporated. Although additional follow-up is required to determine the effect on survival, this modified regimen has significant potential in the management of advanced myeloma.

Key Words. Multiple myeloma • Pegylated liposomal doxorubicin • Thalidomide • Dexamethasone

This article has been cited by other articles:

				M. A. Hussein, R. Baz, G. Srkalovic, N. Agrawal, R. Suppiah, E. Hsi, S. Andresen, M. A. Karam, J. Reed, B. Faiman, et al. Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma Mayo Clin. Proc., July 1, 2006; 81(7): 889 - 895. [Abstract] [Full Text] [PDF]

				J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson Multiple Myeloma Hematology, January 1, 2004; 2004(1): 237 - 256. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky Crossing the Cancer Cell Membrane to Improve Clinical Outcomes Oncologist, December 1, 2003; 8(90003): 1 - 4. [Full Text] [PDF]